Wells Fargo has initiated coverage on Alkermes Plc (ALKS) with an Overweight rating as of September 2, 2025. This rating marks the firm's first assessment of the biopharmaceutical company, which specializes in developing medicines for significant therapeutic areas such as alcohol and opioid dependence, schizophrenia, and bipolar disorder.
Headquartered in Dublin, Alkermes engages in the business of developing, manufacturing, and commercializing treatments aimed at addressing unmet medical needs. The company boasts a market capitalization of $4.7 billion and a P/E ratio of 13.96. Its portfolio includes commercial products like LYBALVI, ARISTADA, and VIVITROL, alongside a robust pipeline focused on neurological disorders and cancer.
Upcoming earnings reports are anticipated, with estimates for July 27, 2026, projecting an EPS of $0.53 and revenue of $483.2 million. Recent earnings performance has been strong, with Q3 2025 EPS reported at $0.49, surpassing estimates by 59.8%. This positive trend underscores the company's growth potential and the implications of Wells Fargo's new coverage.
Analyst ratings, such as this one, serve as insights based on extensive research and financial modeling. However, they reflect assumptions that may evolve as new data emerges. Investors are encouraged to consider a range of factors, including company fundamentals and market conditions, when evaluating potential investments.
Alkermes currently holds a consensus rating of Buy among analysts, with 5 Strong Buy, 13 Buy, and 4 Hold ratings out of a total of 22 analysts surveyed as of November 1, 2025. Analyst opinions can shift with market developments, making it essential for investors to stay informed.